What to partner with, when to approach pharmaceutical companies and how to turn an app into a strategic treatment asset A medicine does not create value when it leaves the …

Why early HTA, health-economic modelling and payer dialogue should begin before the pivotal trial is finalised A medical device, diagnostic or digital-health technology can be safe, technically successful and supported …

An evidence-informed guide to patient-pathway value, reimbursement, strategic fit and acquisition readiness Most healthcare-app founders believe they are building a product. A future buyer may be looking for something entirely …

Germany gives pharmaceutical companies unusually rapid access to a major European market. A newly authorised medicine can generally enter reimbursed use while its comparative benefit and long-term reimbursement amount are …

Receiving FDA clearance or approval is one of the defining moments in a medical technology company’s life. It is also the point at which many companies discover that regulatory success …

UK RWE can support EU market access, but only when clinical, economic and payer evidence is translated for local HTA decisions. The UK remains one of the strongest environments in …